Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956198 · ClinicalTrials.gov registry record
Drug Sensitivity and Mutation Profiling
A clinical trial, sponsored by Florida International University.
- Completed
- Registry status
- 14
- Enrollment target
NCT04956198 is a clinical trial that has completed, run by Florida International University. The registered enrollment target is 14 participants.
The verdict
NCT04956198 has completed, sponsored by Florida International University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956198
The ClinicalTrials.gov registry entry for NCT04956198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Florida International University, which has 89 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04956198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04956198 about?
NCT04956198 is a clinical study titled "Drug Sensitivity and Mutation Profiling". This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (D...
What is the current status of trial NCT04956198?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2020-11-17. Estimated completion is 2022-12-31.
Who is sponsoring clinical trial NCT04956198?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.